Aptose Biosciences, Inc. (APTO) Raised to “Buy” at HC Wainwright
Aptose Biosciences, Inc. (NASDAQ:APTO) (TSE:APS) was upgraded by analysts at HC Wainwright from a “neutral” rating to a “buy” rating in a research note issued on Thursday, Marketbeat Ratings reports. The firm currently has a $4.00 target price on the biotechnology company’s stock, up from their prior target price of $1.00. HC Wainwright’s price objective suggests a potential upside of 166.67% from the company’s previous close.
APTO has been the topic of a number of other reports. Rodman & Renshaw assumed coverage on shares of Aptose Biosciences in a research report on Thursday, June 8th. They set a “neutral” rating on the stock. ValuEngine raised shares of Aptose Biosciences from a “strong sell” rating to a “sell” rating in a research report on Wednesday, July 12th. Canaccord Genuity reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Aptose Biosciences in a research report on Friday, May 12th. Finally, Zacks Investment Research raised shares of Aptose Biosciences from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a research report on Monday, August 14th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. Aptose Biosciences currently has an average rating of “Buy” and an average target price of $6.50.
Shares of Aptose Biosciences (APTO) opened at 1.50 on Thursday. The firm’s 50-day moving average is $1.48 and its 200 day moving average is $1.22. The firm’s market capitalization is $36.04 million. Aptose Biosciences has a 52 week low of $0.78 and a 52 week high of $3.20.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.07. Equities research analysts forecast that Aptose Biosciences will post ($1.61) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Aptose Biosciences, Inc. (APTO) Raised to “Buy” at HC Wainwright” was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/09/10/aptose-biosciences-inc-apto-raised-to-buy-at-hc-wainwright.html.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.